Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Pharmaceuticals"

1678 News Found

Glenmark Pharmaceuticals USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial single-dose vial
News | December 12, 2025

Glenmark Pharmaceuticals USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial single-dose vial

Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug


Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg
News | December 12, 2025

Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg

The product will be marketed by Dr. Reddy's Laboratories Inc.


Briefs: IOL Chemicals & Pharmaceuticals, Ipca Laboratories and Anuh Pharma
News | December 06, 2025

Briefs: IOL Chemicals & Pharmaceuticals, Ipca Laboratories and Anuh Pharma

Ipca Laboratories receives three observations from USFDA for API facility at Tarapur


Senores Pharmaceuticals receives Philippine FDA approval for 10 products
Drug Approval | December 05, 2025

Senores Pharmaceuticals receives Philippine FDA approval for 10 products

Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region


SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
News | November 09, 2025

SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr

SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025


Glenmark Pharmaceuticals USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq Single-Dose Vial
News | November 05, 2025

Glenmark Pharmaceuticals USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq Single-Dose Vial

Glenmark will begin distribution in November 2025


MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain
Clinical Trials | October 29, 2025

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation


Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP
News | October 23, 2025

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA